Blog
RSS FeedPosted by Michael Wonder on 31 Oct 2019
Proposal to widen access to rituximab and change the funded brand for all funded indications excluding rheumatoid arthritis
31 October 2019 - PHARMAC is seeking feedback on a proposal to make changes to the funded brand of rituximab, ...
Posted by Michael Wonder on 22 Oct 2019
Proposal to widen access to bortezomib for multiple myeloma and amyloidosis
22 October 2019 - PHARMAC is seeking feedback on the proposal to change the Special Authority criteria for bortezomib. ...
Posted by Michael Wonder on 07 Aug 2019
Proposal for funding of oncology, multiple sclerosis and respiratory treatments
7 August 2019 - PHARMAC is seeking feedback on a proposal to fund three new treatments and widen access to ...
Posted by Michael Wonder on 06 Aug 2019
Proposals for funding in the immunosuppressant, cardiovascular and anti-nausea therapeutic areas
6 August 2019 - PHARMAC is seeking feedback on proposals for widening access to medicines in the immunosuppressant, cardiovascular and ...
Posted by Michael Wonder on 11 Jul 2019
Proposals for funding in the immunosuppressant, oncology, vasodilator and smoking cessation therapeutic areas
11 July 2019 - PHARMAC is seeking feedback on proposals for funding in the immunosuppressant, oncology, vasodilator and smoking cessation ...
Posted by Michael Wonder on 30 May 2019
Proposals for funding in the neurology, immunosuppressants, diabetes and anti-thrombotic therapy areas
30 May 2019 - PHARMAC is seeking feedback on proposals for funding in the neurology, immunosuppressant, diabetes and anti-thrombotic therapy ...
Posted by Michael Wonder on 18 Dec 2018
Proposal to amend the distribution and access criteria for dasatinib (Sprycel)
18 December 2018 - PHARMAC is seeking feedback on a proposal to amend the distribution arrangements and access criteria for ...
Posted by Michael Wonder on 16 Dec 2018
Proposal to harmonise, streamline and transition the Cancer Drug Implementation Advisory Committee to CADTH
14 December 2018 - Providing customised implementation support to decision-makers at all levels of the health system is a key ...
Posted by Michael Wonder on 11 Dec 2018
Decision to list a new brand of iron polymaltose (Ferrosig)
11 December 2018 - PHARMAC is pleased to announce a decision to list a new brand of iron polymaltose inj ...
Posted by Michael Wonder on 10 Dec 2018
Proposal to open access to atomoxetine and change funded brand
10 December 2018 - PHARMAC is proposing to remove all funding restrictions from all presentations of atomoxetine, and change the ...
Posted by Michael Wonder on 07 Dec 2018
Proposal to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
7 December 2018 - PHARMAC is seeking feedback on a multi-product proposal with Merck Sharpe & Dohme. ...
Posted by Michael Wonder on 30 Nov 2018
Proposal involving treatments for multiple sclerosis, narcolepsy and attention deficit hyperactivity disorder
30 November 2018 - PHARMAC is seeking feedback on a proposal involving the following products through a provisional agreement with ...
Posted by Michael Wonder on 28 Oct 2018
Update on proposal to move to one funded brand of lamotrigine (Logem)
26 October 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to move to one ...
Posted by Michael Wonder on 24 Oct 2018
Further update on proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis C
24 October 2018 - This is a further update on the proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis ...
Posted by Michael Wonder on 06 Sep 2018
Proposal on the funding of infliximab, rituximab and tocilizumab
6 September 2018 - PHARMAC is proposing to change how three hospital medicines are managed within the Pharmaceutical Schedule. ...